Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 235-242

  Tsuchiya, Hiroyuki ^a,b   Mori, Yoshihiko ^a   Ueda, Yoshimichi ^c   Okada, Gensaku ^b   Tomita, Katsuro ^b  

^a School of Medicine   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Caffeine; Cisplatin; Human osteosarcoma; Transfection; Wild type p53

Indexed keywords

CAFFEINE; CISPLATIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE TRANSFER; HUMAN; HUMAN CELL; NICK END LABELING; OSTEOSARCOMA; PRIORITY JOURNAL; SENSITIZATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CAFFEINE; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DRUG SYNERGISM; GENE DELETION; GENES, P53; HUMANS; IN SITU NICK-END LABELING; NEOPLASM PROTEINS; OSTEOSARCOMA; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034073148     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329: 1318-1327, 1993.
3. Levine AJ, Monand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
4. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
5. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
6. Goh HS, Yao J and Smith D R: p53 mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221, 1995.
7. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth J A, Tanaka N and Orita K: The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122: 360-365, 1996.
8. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K and Yandell DW: Mutation spectrum of the p53 gene in bone and soft tissue sarcoma. Cancer Res 52: 6194-6199, 1992.
9. Andreassen A, Oyjord T, Hoving E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresn AL and Fodstadt O: p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53: 468-471, 1993.
10. Ueda Y, Dockhorn-Dworniczack B, Blasius S, Mellin W, Wuisman P, Bocker W and Roessner, A: Analyis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119: 172-178, 1993.
11. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS and Yamamuro T: p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68: 1134-1139, 1993.
12. Mousses S, McAuley L, Bell RS, Kandel R and Andrulis IL: Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9: 1-6, 1996.
13. Lonardo F, Ueda T, Huvos AG, Healey J and Ladanyi M: p53 and MDM2 alterations in osteosarcomas. Cancer 79: 1541-1547, 1997.
14. Tomita K and Tsuchiya H: Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 80: 83-88, 1989.
15. Tomita K and Tsuchiya H: Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma. Clin Ther 11: 43-52, 1989.
16. Masuda H, Miller C, Koeffler HP, Battifora H and Cline MJ: Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84: 7716-7719, 1987.
17. 3, in vivo on human osteosarcoma. J Orthop Res 11: 122-130, 1993.
18. Felger PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
19. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
21. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M and Pingang H: A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 41: 1118-1122, 1993.
22. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
23. Whitaker LL and Hansen MF: Induction of apoptosis in Mv1Lu cells by expression of competitive RBI mutants. Oncogene 15: 1069-1077, 1997.
24. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R and Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells hearing multiple genetic lesions. Cancer Res 52: 2340-2343, 1992.
25. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B and Stanbridge EJ: Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791-1797, 1991.
26. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
27. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW and Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87: 6166-6170, 1990.
28. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
29. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B and Friend SH: p53 functions as a cell cycle control in osteosarcomas. Mol Cell Biol 10: 5772-5781, 1990.
30. Miyakoshi J, Yamagishi N, Ohtsu S and Takebe H: Changes in radiation sensitivity of human osteosarcoma cells after p53 introduction. Jpn J Cancer Res 86: 711-713, 1995.
31. Brown R, Clugston C, Burns P, Edlin P, Vasey P, Vojtesek B and Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684, 1993.
32. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou G and Benard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68: 67-74, 1996.
33. Blagosklonny MV and El-Deiry WS: Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75: 933-940, 1998.
34. Fan S, Smith ML, Rivet DJII, Duba D, Zhan Q, Kohn K W, Fornace AJJr and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
35. Hawkins D, Demers W and Galloway D: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
36. Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292: 435-445, 1998.
37. Elledge RM and Lee WH: Life and death by p53. Bioassays 17: 923-930, 1995.
38. Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 274: 1664-1672, 1996.
39. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995.
40. Pellegata NS, Antoniono RJ, Redpath JL and Stanbridge EJ: DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci USA 93: 15209-15214, 1996.
41. 2 arrest. Radiat Res 76: 292-307, 1978.
42. Fingert HJ, Chang JD and Pardee AB: Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 46: 2463-2467, 1986.
43. Domon M, Barton B, Porte A and Rauth AM: The interaction of caffeine with ultra-violet-light-irradiated DNA. Int J Radiat Biol Relat Stud Phys Chem Med 17: 395-399, 1970.
44. Fraval HNA and Roberts JJ: Effects of cis-platinum(II) diamminedichloride on survival and the rate of DNA synthesis in synchronously growing HeLa cells in the absence and presence of caffeine. Chem Biol Interactions 23: 111-119, 1978.
45. Painter RB: Effect of caffeine on DNA synthesis in irradiated mammalian cells. J Mol Biol 143: 289-301, 1980.
46. Schlegel R and Pardee AB: Caffeine-induced uncoupling of mitosis from the complication of DNA replication in mammalian cells. Science 232: 1264-1266, 1986.
47. Lau CC and Pardee AB: Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79: 2942-2946, 1982.
48. Yasutake H, Tsuchiya H, Tomita K, Matsunaga T, Nikaido O and Mori T: Inhibitory effect of caffeine on potentially lethal damage repair in cisplatin-treated human osteosarcoma cells. Anticancer Res 15: 831-838, 1995.
49. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 5: 6304-6311, 1991.
50. Efferth T, Fabry U, Glatte P and Osieka R: Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol 121: 648-656, 1995.
51. Peled A, Zipori D and Rotter V: Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells. Cancer Res 56: 2148-2156, 1996.
52. Jaffe N, Raymond AK, Ayala A, Carrasco CH, Wallace S, Robertson R, Griffiths M and Wang YM: Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma. Cancer 63: 63-67, 1989.
53. Bacci G, Picci P, Avella M, Ferrari S, Casadei R, Ruggieri P, Brach del Prevert A, Tienghi A, Battistini A and Mancini A: Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. J Chemother 4: 189-195, 1992.
54. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prevert A, Gherlinzoni F, Mercuri M and Monti C: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 72: 3227-3238, 1993.
55. Tsuchiya H, Tomita K, Mori Y, Asada N, Kitano S, Morinaga T and Yamamoto N: Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18: 657-666, 1998.
56. Tsuchiya H, Tomita K, Yamamoto N, Mori Y, Asada N: Caffeine-potentiated chemotherapy for high-grade soft-tissue sarcoma. Anticancer Res 18: 3651-3656, 1998.
57. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Kamaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T and Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2: 985-991, 1996.